Page 6,775«..1020..6,7746,7756,7766,777..6,7806,790..»

InGen BioSciences Group, Exclusive Distributor for Cylex Incorporated in France, Reinforces its Translational Medicine …

Posted: Published on June 14th, 2012

CHILLY-MAZARIN, France, June 14, 2012 /PRNewswire/ -- InGen BioSciences, specialised in the development and commercialisation of mono and multiparametric in vitro diagnostic tests announced a new exclusive partnership with Cylex Incorporated (Columbia, Maryland, US), a global life sciences company focused on in vitro diagnostic products intended to illuminate immunity. With this exclusive partnership with Cylex, InGen BioSciences will provide to the French medical community the only FDA-cleared, CE marked and IVDD compliant assay that detects changes in global immune function over time in patients undergoing immunosuppressive therapy for organ transplant: ImmuKnow. Organ transplantation is an effective therapy for end-stage organ failure and is widely practised around the world. Global Observatory on Donation and Transplantation (GODT) 2010 data (produced by the WHO-ONT collaboration) report 106879 total solid organ transplants per year of which 73179 kidney transplants , 21 602 liver transplants and 5 582 heart transplants(1). Studies show that long-term use of immunosuppressants is associated with significant morbidity and mortality in transplant recipients and current monitoring systems of immunosuppression in those patients are typically focused on prevention of clinical toxicities of immunosuppressive drugs. Minimising the risk of infection and rejection in post-transplant patients is therefore crucial and challenging for clinicians.(2-5) Unfortunately, … Continue reading →

Posted in Cell Medicine | Comments Off on InGen BioSciences Group, Exclusive Distributor for Cylex Incorporated in France, Reinforces its Translational Medicine …

Cell Therapeutics Appoints New Chief Medical Officer

Posted: Published on June 14th, 2012

June 14, 2012, SEATTLE /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI") (NASDAQ and MTA: CTIC), a company focused on translating science into novel cancer therapies, today announced that former OncoMed Pharmaceuticals executive, Steven E. Benner, M.D., M.H.S., has joined CTI as Executive Vice President and Chief Medical Officer ("CMO"), reporting to James A. Bianco, M.D., Chief Executive Officer. Dr. Benner will take over all drug development activities at the company.Dr. Benner was previously senior vice president and chief medical officer at OncoMed, a venture-backed biotechnology company focused on the development of cancer stem cell targeting agents. Prior to OncoMed, he was CMO at Protein Design Labs ("PDL"), where he was accountable for all development activities including clinical development, clinical operations, biometry, regulatory affairs, and safety. He also served as Chair of the Portfolio and Clinical Development Management Committees of PDL. Before PDL he held several senior executive roles at Bristol-Myers Squibb in global development, life cycle management, and licensing and alliances. "Dr. Benner brings to CTI his proven track record of success in advancing the development of innovative therapies for cancer patients," said Dr. Bianco. "His appointment is the first step in re-aligning our portfolio efforts, as we focus on advancing … Continue reading →

Posted in Cell Medicine | Comments Off on Cell Therapeutics Appoints New Chief Medical Officer

Oncolytics Biotech® Inc. Announces Publication of Translational Clinical Trial Results in Science Translational Medicine

Posted: Published on June 14th, 2012

CALGARY , June 13, 2012 /CNW/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that a paper entitled "Cell Carriage, Delivery, and Selective Replication of an Oncolytic Virus in Tumor in Patients," has been published in the latest issue of the journal Science Translational Medicine (Vol. 4 Issue 138 138ra77). The paper covers findings from a U.K. translational clinical trial (REO 013) investigating intravenous administration of REOLYSIN in patients with metastatic colorectal cancer prior to surgical resection of liver metastases. The paper was jointly first-authored by researchers from the Leeds Institute of Molecular Medicine, University of Leeds , UK and The Institute of Cancer Research, London , UK. The trial was an open-label, non-randomized, single centre study of REOLYSIN given intravenously to patients for five consecutive days in advance of their scheduled operations to remove colorectal cancer metastasis in the liver. Ten patients were treated with intravenous REOLYSIN at 1x1010 TCID50, one to four weeks prior to planned surgery. After surgery, the tumor and surrounding liver tissue were assessed for viral status and anti-tumor effects. The researchers demonstrated that even though all the treated patients had preexisting immunity to the virus, intravenously administered reovirus could still specifically target and … Continue reading →

Posted in Cell Medicine | Comments Off on Oncolytics Biotech® Inc. Announces Publication of Translational Clinical Trial Results in Science Translational Medicine

International Stem Cell Corporation Scientists Create New Protein-Based Stem Cell Technology

Posted: Published on June 14th, 2012

CARLSBAD, Calif.--(BUSINESS WIRE)-- International Stem Cell Corporation (ISCO) http://www.internationalstemcell.com announced that scientists in its wholly-owned subsidiary, Lifeline Cell Technology (LCT), have developed a technology to modify human stem cells by using engineered proteins, called "transducible transcription factors" or "TTFs." TTFs are designed to pass into stem cells and direct the stem cells to change into specific cell types that can be both therapeutically-useful and can be used as revenue-generating research products. In contrast to more traditional cell therapy methods this technology does not require the use of viruses or chemicals, and has the potential to produce safe therapeutic cells from stem cells. In addition, the TTF proteins are naturally eliminated by the cells when no longer required, a characteristic that further improves safety. The Company intends that this technology, once perfected, will first be used to create revenue-generating research products for sale through Lifeline Cell Technologys international distribution channels to the academic, biotechnology and pharmaceutical markets for cellular proteins, including the quickly growing markets for the study of stem cell biology and drug testing. According to Jeffrey Janus, Lifeline Cell Technologys CEO, These proteins can be sold into the market for cellular proteins which exceeds $700 million and represents an … Continue reading →

Posted in Cell Therapy | Comments Off on International Stem Cell Corporation Scientists Create New Protein-Based Stem Cell Technology

Osiris Receives Second Approval for Life-Saving Stem Cell Drug; Prochymal Granted Marketing Consent by New Zealand

Posted: Published on June 14th, 2012

COLUMBIA, Md.--(BUSINESS WIRE)-- Osiris Therapeutics, Inc. (OSIR), announced today it has received consent from New Zealand to market its first-in-class stem cell therapy Prochymal (remestemcel-L), for the treatment of acute graft-vs-host disease (GvHD) in children. With this decision New Zealand joins Canada, which last month became the worlds first internationally recognized regulatory authority to grant approval to a stem cell drug. Prochymal is also the first therapy approved for GvHD - a devastating complication of bone marrow transplantation that kills up to 80 percent of children affected, many within just weeks of diagnosis. "With each of our approvals it becomes clearer that the time for life-saving stem cell therapies in the practice of medicine has arrived, and we are humbled to have a leading role, said C. Randal Mills, Ph.D., President and Chief Executive Officer of Osiris. I would like to thank the professionals at Medsafe for their thoughtful and expeditious review of this complex application. I would also like to thank the team at Osiris that continues to do an outstanding job of making Prochymal available to children around the world suffering from the devastating effects of GvHD." Osiris submitted a New Medicine Application (NMA) to Medsafe(New Zealand's medical … Continue reading →

Posted in Cell Therapy | Comments Off on Osiris Receives Second Approval for Life-Saving Stem Cell Drug; Prochymal Granted Marketing Consent by New Zealand

Dangerous designer drug wreaks havoc

Posted: Published on June 14th, 2012

Readmore: Local, News, Munnsville, Miami, Bath Salts, Drugs, Illegal Drugs, Poison Control, Violence, Pamela Mccarthy Scene in Munnsville where police say a woman was high on bath salts and assaulted her own child before she died following a Taser shock. SYRACUSE -- Bath salts are synthetic drug that users can take just about any way they please eating them, injecting them, snorting or smoking them. But this now-illegal designer drug acts like a dangerous combination of LSD, PCP and cocaine. "Essentially, it's a drug-induced psychosis, said Clinical Toxicologist Dr. Alexander Garrard from SUNY Upstate Medical University. So they're not who they think they are. They're acting very different from themselves. They don't even recollect what happened to them. They blank out or black out, if you will. And that's maybe perhaps related to some of the cannibalistic behavior. It's really reducing them to primal instincts." The cannibalistic behavior resulting from bath salts has been making startling headlines.The firstcame over Memorial Day weekend when a homeless Miami, Florida man had his face devoured by a man high on bath salts.Another incidentin Miami happened on Monday when a half-naked man approached a three-year-old girl on a playground for sex. Police say the … Continue reading →

Posted in Drug Side Effects | Comments Off on Dangerous designer drug wreaks havoc

Dear Pharmacist: Educate yourself about side effects

Posted: Published on June 14th, 2012

Dear Pharmacist: Ive recently developed minor numbness and tingling in my hands. Could it be a side effect my medications? Im scared of what else could cause this. S.L., Santa Rosa, Calif. A: Oh boy, l love talking about side effects. Obviously, consult your doctor to rule out other causes, but the simple answer is Yes! Most practitioners today are not aware that side effects are often the result of drug nutrient depletions, what I call the drug mugging effect. Im happy to say this concept has gained traction in the medical community, partly because Ive been hammering it in the media for 13 years and also because I published a book on it called Drug Muggers. Theres another layer to consider. We all have unique genetic SNPs (pronounced snips) in our DNA code that cause us to process medications, foods and nutrients a little differently from one another. For example, most autistic children and 20 percent of the general population are poor methylators and thus, need a nutritional helping hand, usually folic acid; vitamin B6, B12 (methylcobalamin), and SAMe are useful, too. These deficiencies may cause numbness and tingling in your extremities, and a host of other plaguing disorders. … Continue reading →

Posted in Drug Side Effects | Comments Off on Dear Pharmacist: Educate yourself about side effects

South Africa: Deaf or Dead? Better Drugs Needed to Stop Drug-Resistant TB

Posted: Published on June 14th, 2012

Cases of drug-resistant tuberculosis will continue to increase unless scientists develop more effective medicines with fewer side effects. This has emerged as one of the key issues at the third South African tuberculosis conference, which opened last night (Tues) in Durban. At present, people with drug-resistant TB face almost two years' of treatment, including a daily injection for the first six months. Despite this punishing regimen, less than half the cases of drug-resistant TB were cured in South Africa last year, according to the World Health Organisation. A number of patients also stop treatment because they cannot tolerate the side effects. "Treatment for drug-resistant TB is ineffective. It is too long, there are significant side-effects and it is expensive," according to Dr Helen Cox of Medicins sans Frontieres. "Aside from the daily injections that are very painful, 30 percent of people with drug-resistant TB develop hearing loss that is irreversible as a side-effect of the drugs," said Cox. "If someone starts going deaf a few weeks into treatment, what do we do? They need to continue with their treatment, but this means they will either be deaf or dead. This highlights the urgent need for new drugs." The Treatment Action … Continue reading →

Posted in Drug Side Effects | Comments Off on South Africa: Deaf or Dead? Better Drugs Needed to Stop Drug-Resistant TB

Turkey: Ex-president's death is 'suspicious'

Posted: Published on June 14th, 2012

By SELCAN HACAOGLU Associated Press ANKARA, Turkey (AP) - The 1993 death of Turkey's then-President Turgut Ozal is suspicious and should be investigated, a report by the presidential palace said Wednesday. The report said there has been no satisfactory investigation into allegations by some family members and lawmakers that Ozal, whose pro-Western policies helped modernize Turkey and gave the U.S.-led coalition a strategic ally during the Persian Gulf War, might have been poisoned. The report by the State Auditing Board, which is under the direct supervision of President Abdullah Gul, cautioned that most of the allegations were "intangible," but suggested an autopsy and a hair sample test could confirm for certain the cause of death. It said the results of the president's blood tests, as well as his blood samples, were missing. Doctors at the time said Ozal, who underwent triple bypass surgery in 1987, died of heart failure on April 17, 1993. But, the president's wife, Semra Ozal, has claimed she received a note in 1998 that said her husband was poisoned and has told several television stations that Ozal died a day after drinking lemonade at a reception in Ankara. The report said Ozal apparently consumed fresh orange … Continue reading →

Posted in Wholesale Pharmacy | Comments Off on Turkey: Ex-president's death is 'suspicious'

Jobs not handouts will drag families out of poverty, IDS tells parents as he unveils plans to tackle welfare dependency

Posted: Published on June 14th, 2012

Majority of children lifted out of poverty if one parent works 35 hours a week at the minimum wage or 24 hours if they are a lone parent, under reforms Handouts helps fuel drug addiction and welfare dependency, Ian Duncan Smith with declare Changes aimed at turning around troublesome families By James Chapman PUBLISHED: 18:32 EST, 13 June 2012 | UPDATED: 05:26 EST, 14 June 2012 Parents should get a job rather than rely on handout if they want to lift their children out of poverty, Iain Duncan Smith will declare today. The Work and Pensions Secretary will insist that employment, not a few extra pounds in welfare benefits, is the key to lifting families out of poverty, as he unveils plans to replace all other out of work benefits from 2013, with the Coalitions new universal credit. Mr Duncan Smith claims the reform will remove incentives to stay on welfare rather than moving into work. New targets: Iain Duncan Smith Mr Duncan Smith will also announce plans to tear up the method of measuring child poverty by family income, introduced under Labour, insisting that determining childrens wellbeing simply on the basis of income can be perverse. He will claim … Continue reading →

Posted in Drug Dependency | Comments Off on Jobs not handouts will drag families out of poverty, IDS tells parents as he unveils plans to tackle welfare dependency

Page 6,775«..1020..6,7746,7756,7766,777..6,7806,790..»